<DOC>
	<DOCNO>NCT00316719</DOCNO>
	<brief_summary>This study design compare efficacy safety adefovir dipivoxil 10 mg lamivudine 100 mg Japanese patient compensate chronic hepatitis B 52-week period .</brief_summary>
	<brief_title>Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion criterion : Have compensate chronic hepatitis B . Have treat anti HBV agent antiproliferative activity . However , previous Interferon ( IFN ) therapy permit . Ability read , understand , sign inform consent . Have positive serum HBVDNA &gt; = 1,000,000 copies/mL ALT level 50500 U/L Exclusion criterion : Having suspect liver cancer . Coinfected Hepatitis C virus ( HCV ) Human Immunodeficiency virus ( HIV ) . Autoimmune hepatitis . Received previous transplantation plan transplantation . Existence serious complication , except hepatitis B .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>treatment naive</keyword>
	<keyword>CHB</keyword>
	<keyword>adefovir</keyword>
	<keyword>monotherapy</keyword>
</DOC>